IL18 and myeloid sarcoma: However, in the serum of MS patients undergoing IFN-β treatment substantially lower levels of IL-1β, IL-12/23p40, IL-18, TNF-α, and HMGB-1 and higher levels of IL-18BP and ACh were detected.